Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.58 |
| ▸ | MAOB | P27338 | 1/20 | 0.58 |
| ▸ | NPC1 | O15118 | 3/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | BLM | P54132 | 1/20 | 0.57 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | GFER | P55789 | 1/20 | 0.51 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14562080 | 0.84 | NPC1 (0.65) | SMN1; SMN2NPC1MEN1KMT2ARAB9A | |
| SCHEMBL3499586 | 0.83 | SMN1; SMN2 (0.83) | SMN1; SMN2NPC1KMT2ARAB9AGAA | |
| SCHEMBL9585652 | 0.83 | CYP1A2 (0.70) | SMN1; SMN2CYP1A2TSHRNFKB1MAOB | |
| SCHEMBL7772373 | 0.83 | SMN1; SMN2 (0.57) | SMN1; SMN2CYP1A2TSHRNFKB1MAOB | |
| SCHEMBL13593317 | 0.82 | SMN1; SMN2 (0.60) | SMN1; SMN2CYP1A2MEN1KMT2AMAPT | |
| SCHEMBL8404711 | 0.81 | SMN1; SMN2 (0.55) | SMN1; SMN2CYP1A2TSHRNFKB1MAOB | |
| SCHEMBL8404712 | 0.81 | SMN1; SMN2 (0.55) | SMN1; SMN2NPC1KMT2ARAB9ACA2 | |
| SCHEMBL12279683 | 0.81 | NPC1 (0.65) | SMN1; SMN2NFKB1NPC1KMT2ARAB9A | |
| SCHEMBL3038665 | 0.81 | SMN1; SMN2 (0.58) | SMN1; SMN2NPC1KMT2ARAB9ACA2 | |
| SCHEMBL9584535 | 0.80 | CYP1A2 (0.78) | SMN1; SMN2CYP1A2TSHRNFKB1MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170189443-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES AND CONDITIONS EMPLOYING ORAL ADMINISTRATION OF SODIUM PENTOSAN POLYSULFATE AND OTHER PENTOSAN POLYSULFATE SALTS | PLATINUM MONTAUR LIFE SCIENCES, LLC AND AS AGENT (KY) | 2017-07-06 | — | — | US | claimed |
| EP-3110427-A1 | COMPOSITIONS OF PENTOSAN POLYSULFATE SALTS FOR ORAL ADMINISTRATION AND METHODS OF USE | Urigen Pharmaceuticals, Inc. (US) | 2017-01-04 | — | — | EP | claimed |
| WO-2015127416-A1 | COMPOSITIONS OF PENTOSAN POLYSULFATE SALTS FOR ORAL ADMINISTRATION AND METHODS OF USE | URIGEN PHARMACEUTICALS, INC. (US) | 2015-08-27 | — | — | WO | claimed |
| EP-1015008-A4 | COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS | EMISPHERE TECH INC (US) | 2006-08-09 | — | — | EP | claimed |
| EP-1015008-A1 | COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS | Emisphere Technologies, Inc. (US) | 2000-07-05 | — | — | EP | claimed |
| WO-1998034632-A9 | COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS | EMISPHERE TECH INC (US) | 1999-09-02 | — | — | WO | claimed |
| WO-1998034632-A1 | COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS | EMISPHERE TECHNOLOGIES, INC. (US) | 1998-08-13 | — | — | WO | claimed |
| US-20170189443-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES AND CONDITIONS EMPLOYING ORAL ADMINISTRATION OF SODIUM PENTOSAN POLYSULFATE AND OTHER PENTOSAN POLYSULFATE SALTS | PLATINUM MONTAUR LIFE SCIENCES, LLC AND AS AGENT (KY) | 2017-07-06 | — | — | US | disclosed |
| EP-3110427-A1 | COMPOSITIONS OF PENTOSAN POLYSULFATE SALTS FOR ORAL ADMINISTRATION AND METHODS OF USE | Urigen Pharmaceuticals, Inc. (US) | 2017-01-04 | — | — | EP | disclosed |
| WO-2015127416-A1 | COMPOSITIONS OF PENTOSAN POLYSULFATE SALTS FOR ORAL ADMINISTRATION AND METHODS OF USE | URIGEN PHARMACEUTICALS, INC. (US) | 2015-08-27 | — | — | WO | disclosed |
| US-20090324540-A1 | COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS | EMISPHERE TECHNOLOGIES, INC. (US) | 2009-12-31 | — | — | US | disclosed |
| US-20090324540-A1 | COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS | EMISPHERE TECHNOLOGIES, INC. (US) | 2009-12-31 | — | — | US | disclosed |
| US-7553872-B2 | Compounds and compositions for delivering active agents | EMISPHERE TECHNOLOGIES, INC. (US) | 2009-06-30 | — | — | US | disclosed |
| US-7071214-B2 | Compounds and compositions for delivering active agents | EMISPHERE TECHNOLOGIES, INC. (US) | 2006-07-04 | — | — | US | disclosed |
| EP-0477912-B1 | Novel N-acyldipeptides, and pharmaceutical compositions containing the same | UNIV LJUBLJANI (SI) | 2001-08-29 | — | — | EP | disclosed |
| EP-1015008-A1 | COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS | Emisphere Technologies, Inc. (US) | 2000-07-05 | — | — | EP | disclosed |
| WO-1998034632-A9 | COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS | EMISPHERE TECH INC (US) | 1999-09-02 | — | — | WO | disclosed |
| WO-1998034632-A1 | COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS | EMISPHERE TECHNOLOGIES, INC. (US) | 1998-08-13 | — | — | WO | disclosed |
| US-5514654-A | ANTITUMOR AGENTS AND IMMUNOMODULATORS | UNIV LJUBLJANI (SI) | 1996-05-07 | — | — | US | disclosed |
| EP-0477912-A2 | Novel N-acyldipeptides, processes for the preparation thereof and pharmaceutical compositions containing the same | UNIVERZA EDVARDA KARDELJA V LJUBLJANI, VDO FAKULTETA ZA NARAVOSLOVJE IN TEHNOLOGIJO, N.SOL.O., LUBLJANA (YU) | 1992-04-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090324540-A1 | COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS | ABCB4, ABCB7, ALPP | SMN1; SMN2 225/4885CYP1A2 3436/4885TSHR 3659/4885 |
| US-20170189443-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES AND CONDITIONS EMPLOYING ORAL ADMINISTRATION OF SODIUM PENTOSAN POLYSULFATE AND OTHER PENTOSAN POLYSULFATE SALTS | SI, SLC20A1, SLC20A2 | SMN1; SMN2 366/4885CYP1A2 1899/4885TSHR 4340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.